Related Experiment Video

Updated: Jun 16, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations

Jonathan D Roth1, James L Trevaskis, Victoria F Turek

  • 1Amylin Pharmaceuticals, Inc., San Diego, CA 92121, USA. jonathan.roth@amylin.com

Brain Research
|January 26, 2010
PubMed

Insights

Combinatorial approaches may overcome weight loss resistance. Combining hormones like amylin and leptin shows synergistic effects, offering a promising strategy for effective anti-obesity treatments.

Area of Science:

  • Neuroendocrinology
  • Metabolic Regulation
  • Pharmacology

Background:

  • Weight loss and maintenance trigger counter-regulatory responses, limiting single-agent anti-obesity drug efficacy.
  • Neurochemical pathways are significantly altered during negative energy balance.
  • Understanding these responses is crucial for developing sustainable weight management strategies.

Purpose of the Study:

  • To explore combinatorial strategies for overcoming anti-obesity treatment resistance.
  • To discuss preclinical modeling of synergistic weight loss combinations.
  • To highlight the potential of neurohormonal synergies in anti-obesity therapy.

Main Methods:

  • Review of translational research on naturally occurring neurohormonal synergies.
  • Examination of methodological and practical considerations for preclinical combination studies.
  • Analysis of pharmacological and mechanistic data from combined amylin and leptin administration.

Main Results:

  • Combinatorial approaches show potential to overcome counter-regulatory responses to weight loss.
  • Preclinical modeling strategies are being developed for additive/synergistic weight loss combinations.
  • Combined amylin and leptin administration demonstrates synergistic effects.

Conclusions:

  • Combinatorial therapies represent a promising strategy to enhance anti-obesity treatment efficacy.
  • Further research into neurohormonal synergies is warranted for novel therapeutic development.
  • Future anti-obesity treatments may involve combination therapies targeting multiple pathways.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...